Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
RIVM designated as WHO Collaborating Centre Antimicrobial Resistance Epidemiology and Surveillance AMR is one of the major global challenges in infectious disease control.